Full-Time

Director of Portfolio Management

Ablation

Varian

Varian

5,001-10,000 employees

Tech-enabled radiation oncology hardware and software

Compensation Overview

$181.3k - $249.3k/yr

+ Commission

No H1B Sponsorship

Remote in USA + 1 more

More locations: Remote in Australia

Remote

Bachelor's, Master's

Category
Business & Strategy (1)
Required Skills
Microsoft Office
Market Research
Financial analysis
Word/Pages/Docs
Excel/Numbers/Sheets
PowerPoint/Keynote/Slides

Get referred to Varian

See people who can refer or advise you

Requirements
  • At least 10 years of related experience in medical device, medtech, life sciences, or healthcare portfolio or product management, including demonstrated experience leading cross-functional teams, portfolio initiatives, or matrixed programs.
  • A bachelor's degree or equivalent is required.
  • The candidate must be able to influence, align, and lead cross-functional stakeholders in a matrixed global environment and demonstrate executive communication, interpersonal, and decision-making skills.
  • Proficiency in Microsoft Office Suite, including Word, Excel, and PowerPoint, and email platforms is required.
  • Extensive professional expertise in interventional oncology, embolization and ablation technologies, image-guided therapy, procedural software, or related medical device markets is required, with the ability to solve complex, multidimensional portfolio challenges.
  • Strong professional judgment and decision-making skills are required.
Responsibilities
  • Lead the development and execution of portfolio strategies for the ablation segment, including IntelliBlate Microwave Ablation and My Ablation Guide supporting treatment-planning, guidance, and confirmation software.
  • Identify market opportunities, define portfolio priorities, inform lifecycle strategy, and develop investment and pricing recommendations that support global growth objectives.
  • Translate broad business strategies into structured portfolio strategies by defining product direction, strategic positioning, value propositions, market insights, portfolio assessments, roadmap priorities, and sellable feature requirements.
  • Collaborate with New Product Introductions, Research and Development, engineering, manufacturing, sales, Medical Affairs, Regulatory Affairs, Global Product Management, and Commercial Marketing to drive innovation, validate concepts, define strategic requirements, and enhance existing offerings.
  • Align portfolio decisions with business goals measured by revenue contribution, customer acquisition efficiency, and marketing-generated pipeline value.
  • Develop and implement strategic plans, market-entry recommendations, customer segmentation, value propositions, and positioning strategies for the microwave ablation and software-solutions portfolio.
  • Identify and collaborate on business-development opportunities, validate market analysis, and create actionable strategies to achieve company objectives.
  • Engage external business and industry experts to inform and influence business strategies and identify growth opportunities.
  • Conduct market research, trend analysis, and customer segmentation to identify unmet needs, emerging opportunities, and risks related to the microwave ablation and software-solutions market segments.
  • Provide data-driven recommendations to guide the product pipeline and portfolio strategy.
  • Create strategy maps covering goals, objectives, strategies, SWOT analysis, proposed SWOT-based tactics, and competitive analysis, including competing treatment modalities where applicable to total addressable market.
  • Develop, maintain, and communicate portfolio roadmaps; lead opportunity screening, business-case evaluation, investment recommendations, and resource prioritization.
  • Monitor portfolio performance and recommend investment, sustainment, expansion, partnership, acquisition, or retirement actions as appropriate.
  • Work with Medical Affairs and other stakeholders to inform portfolio strategy, address clinical evidence gaps, and align evidence-generation efforts with commercial strategy.
  • Evaluate market opportunities and develop business cases for new products, features, and enhancements to maintain clinical relevance.
  • Collaborate on regulatory plans covering priority markets, rationale, and language strategy.
  • Identify and collaborate on potential new markets and target customer segments.
  • Analyze competitor strategies, pricing models, and product portfolios to identify differentiation opportunities.
  • Establish portfolio-level positioning, claims, differentiation strategies, and value messaging for downstream commercialization.
  • Establish and nurture partnerships with complementary businesses or influencers to expand brand reach and drive growth.
  • Build partnerships within the Siemens Healthineers ecosystem to support new product and service development.
  • Build external partnerships with industry societies, medical societies, hospital groups, and research firms to support insights, research relationships, therapy advancement, technology development, and research.
  • Partner with New Product Introductions, Corporate and Business Development, Research and Development, Global Product Management, Commercial Leaders, and other stakeholders to align priorities with portfolio strategy and customer needs.
  • Partner with Global Product Marketing and Commercial Marketing to translate portfolio strategy into commercialization plans.
  • Monitor market adoption, portfolio performance, and strategic outcomes to inform portfolio decisions and roadmap updates.
  • Partner with Finance to develop financial models and return-on-investment analyses that prioritize product-development and marketing investments.
  • Ensure marketing efforts deliver measurable business outcomes and support revenue-growth targets.
Desired Qualifications
  • A master's degree is preferred.
  • Experience with portfolio management, market modeling, financial analysis, business case development, and roadmap planning tools is preferred.

Varian, part of Siemens Healthineers, focuses on oncology by providing integrated radiation oncology solutions that combine software, hardware, patient data, and care teams. Its offerings include treatment-planning software, radiation therapy machines, and data-management systems that work together to enable precise cancer treatments. The company differentiates itself through an integrated platform approach and services like Oncology-as-a-Service (OaaS), which lets healthcare providers adopt advanced radiation oncology with ongoing service support rather than large upfront investments. Varian serves healthcare providers such as hospitals and cancer centers, helping them deliver coordinated care and improve patient outcomes. Its goal is to reduce the fear of cancer by using data and technology to support clinicians in delivering effective treatments.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

Palo Alto, California

Founded

1948

Get referred to Varian

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • ARPA-H awarded Varian up to $60 million in April 2026 for photon FLASH-RT.
  • FDA cleared TrueBeam for osteoarthritis in March 2026, expanding addressable uses beyond cancer.
  • CE mark for Eclipse AI contouring in May 2026 accelerates European software uptake.

What critics are saying

  • RaySearch enabled online adaptive TrueBeam workflows in Belgium, pressuring Varian's software moat by 2026.
  • PwC's April 2026 Tax Court loss narrows Varian's Section 245A benefit and cash flexibility.
  • If Ethos and Eclipse lose workflow leadership, Varian becomes a commodity linac vendor.

What makes Varian unique

  • TrueBeam, Ethos, Halcyon, and Eclipse create a tightly integrated imaging-to-treatment stack.
  • Siemens Healthineers gives Varian direct hospital access and shared imaging distribution worldwide.
  • Varian controls over 60 percent market share after adding AI planning and adaptive radiotherapy.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible Work Hours

Remote Work Options

Paid Vacation

Paid Holidays

Health Insurance

Dental Insurance

Vision Insurance

Wellness Program

401(k) Retirement Plan

Growth & Insights and Company News

Headcount

6 month growth

5%

1 year growth

5%

2 year growth

5%
MEDQOR
Apr 30th, 2026
Siemens Healthineers secures $83M to develop photon Flash radiotherapy for cancer treatment

Siemens Healthineers has received up to $60 million from the US Advanced Research Projects Agency for Health to develop photon Flash radiotherapy, with the company contributing an additional $23 million, totalling $83 million over five years. Flash photon therapy delivers radiotherapy more than 100 times faster than current technologies, aiming to reduce side effects and improve healthy tissue sparing. Unlike proton and electron beam platforms, which face scalability challenges, photon beams are the standard of care for over 50% of cancer patients. The project will build on existing C-arm linear accelerators to enable broader clinical access. Siemens Healthineers aims to transition ultra-high dose rate radiotherapy from experimental treatment into global standard of care within the five-year timeframe.

Business Wire
Mar 19th, 2026
Varian TrueBeam gets FDA clearance for low-dose radiotherapy to treat osteoarthritis

Siemens Healthineers has received FDA 510(k) clearance for its Varian TrueBeam radiotherapy systems to treat medically refractory osteoarthritis in adults using low-dose radiation therapy. This marks the first expansion of Varian's radiotherapy platform beyond cancer care into chronic musculoskeletal conditions. Osteoarthritis affects over 33 million adults in the US and approximately 600 million globally. The clearance covers TrueBeam, TrueBeam STx, VitalBeam and Edge systems, offering patients with persistent pain a non-invasive outpatient treatment option that targets inflammation, reduces pain and improves joint function. The approval builds on Varian's previous regulatory clearances for non-oncological indications, including radiosurgery treatment for medically refractory essential tremor. The TrueBeam platform combines high-resolution imaging with precise dose control whilst maintaining streamlined clinical workflows.

AuntMinnieEurope.com
Dec 10th, 2025
Telix and Varian enter research collaboration

Telix and Varian enter research collaboration. Telix Pharmaceuticals and Siemens Healthineers' company Varian have agreed to develop novel clinical applications that combine Telix's theranostics products and Varian's external beam radiation therapy (EBRT) technology. The first area of focus will be in identifying opportunities to use Telix's prostate cancer PET imaging agents in selecting patients for EBRT, developing personalized treatment plans (particularly in the context of Varian's Ethos adaptive radiotherapy system), and monitoring responses to treatment, Telix said. The agreement supports both company-sponsored and investigator-led clinical studies. Varian is a key player in EBRT and working with the company will allow Telix to explore how theranostics can be used more effectively by radiation oncologists to enhance patient selection and deliver targeted treatment, Telix noted. I agree to receive marketing related digital communications about products, services, events and offers that may be relevant to my given user preferences and behavior. I agree to share my information with the sponsor. I have read and agree to the privacy policy & terms of service and wish to opt-in.

AuntMinnie.com
Mar 28th, 2025
Varian, Embolx sign image-guided microcatheter agreement

Siemens Healthineers company Varian has entered into a sales and marketing agreement with Embolx for its Sniper Balloon Occlusion Microcatheter.

PR Newswire
Jul 29th, 2024
Varian Announces Future-Focused, Integrated Microwave Ablation Ecosystem With Intelliblate

PALO ALTO, Calif., July 29, 2024 /PRNewswire/ -- Varian, a Siemens Healthineers company, announces receipt of 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its IntelliBlate microwave ablation system, intended for ablation of soft tissue. Designed to provide clinicians with greater predictability, precision, and control during their procedures, IntelliBlate serves as the cornerstone of a future-focused, integrated ecosystem for microwave ablation.IntelliBlate produces large, controlled spherical ablation zones for predictable treatment delivery. With the option to utilize a single or dual probes – each with linked or independent controls – IntelliBlate delivers the versatility to meet the unique clinical needs of each patient. Precision and control are amplified by the Ximitry probe, which enables innovative features such as Laser Disk Alignment and intuitive LED indicators.The compact, versatile design and intuitive interface of IntelliBlate delivers a portable and flexible system that reduces barriers for this important treatment method. Modular elements provide the flexibility for clinicians to expand their treatment capabilities to meet changing clinical demands, all while keeping control over operational efficiency throughout the ablation procedure."IntelliBlate combines the features our customers say are most important for an efficient, integrated solution to seek improved levels of performance in microwave ablation," says Dr